These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34427029)

  • 1. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study.
    Parsonson AO; Connolly E; Lee M; Hruby G; Sandroussi C; Merrett N; Samra J; Mittal A; Tse R; Grimison P
    ANZ J Surg; 2021 Nov; 91(11):2447-2452. PubMed ID: 34427029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
    Patel M; Hoffe S; Malafa M; Hodul P; Klapman J; Centeno B; Kim J; Helm J; Valone T; Springett G
    J Surg Oncol; 2011 Aug; 104(2):155-61. PubMed ID: 21520097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
    Trinh KV; Fischer DA; Gardner TB; Smith KD
    Front Oncol; 2020; 10():1461. PubMed ID: 33042792
    [No Abstract]   [Full Text] [Related]  

  • 9. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
    Heinrich S; Schäfer M; Weber A; Hany TF; Bhure U; Pestalozzi BC; Clavien PA
    Ann Surg; 2008 Dec; 248(6):1014-22. PubMed ID: 19092346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center.
    Curto EM; Kaza AG; Sturdevant DA; Tuvin DM; Ganai S; Sticca RP
    Am J Surg; 2022 Dec; 224(6):1426-1431. PubMed ID: 36372580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
    Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
    PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.
    Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L
    Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
    Tang K; Lu W; Qin W; Wu Y
    Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
    Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
    Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.